Sign in to see private stats on your profile page — or add photo, interests, videos, mentoring, etc.

    Steven Barriere, PharmD

    TitleClinical Professor
    SchoolUCSF School of Pharmacy
    DepartmentClinical Pharmacy
    Address533 Parnassus Avenue
    San Francisco CA 94117
    Phone415-476-2352
    vCardDownload vCard

      Collapse Biography 
      Collapse Education and Training
      University of California, San FranciscoPharm.D. Pharmacy1973

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Lacy MK, Stryjewski ME, Wang W, Hardin TC, Nogid B, Luke DR, Shorr AF, Corey GR, Barriere SL. Telavancin hospital-acquired pneumonia trials: impact of Gram-negative infections and inadequate Gram-negative coverage on clinical efficacy and all-cause mortality. Clin Infect Dis. 2015 Sep 15; 61 Suppl 2:S87-93. PMID: 26316562.
        View in: PubMed
      2. Pushkin R, Barriere SL, Wang W, Corey GR, Stryjewski ME. Telavancin for Acute Bacterial Skin and Skin Structure Infections, a Post Hoc Analysis of the Phase 3 ATLAS Trials in Light of the 2013 FDA Guidance. Antimicrob Agents Chemother. 2015 Oct; 59(10):6170-4. PMID: 26248356; PMCID: PMC4576104.
      3. Worboys PD, Wong SL, Barriere SL. Pharmacokinetics of intravenous telavancin in healthy subjects with varying degrees of renal impairment. Eur J Clin Pharmacol. 2015 Jun; 71(6):707-14. PMID: 25939708; PMCID: PMC4430595.
      4. Barriere SL. Clinical, economic and societal impact of antibiotic resistance. Expert Opin Pharmacother. 2015 Feb; 16(2):151-3. PMID: 25483564.
        View in: PubMed
      5. Corey GR, Rubinstein E, Stryjewski ME, Bassetti M, Barriere SL. Potential role for telavancin in bacteremic infections due to gram-positive pathogens: focus on Staphylococcus aureus. Clin Infect Dis. 2015 Mar 1; 60(5):787-96. PMID: 25472944; PMCID: PMC4329924.
      6. McConeghy KW, Liao S, Clark D, Worboys P, Barriere SL, Rodvold KA. Variability in telavancin cross-reactivity among vancomycin immunoassays. Antimicrob Agents Chemother. 2014 Dec; 58(12):7093-7. PMID: 25223996; PMCID: PMC4249549.
      7. Barriere SL, Farrell DJ, Rhomberg PR, Jones RN. Serum inhibitory and bactericidal activity of telavancin in non-infected subjects with severe renal impairment or end-stage renal disease. Diagn Microbiol Infect Dis. 2014 Dec; 80(4):327-9. PMID: 25306423.
        View in: PubMed
      8. Stryjewski ME, Lentnek A, O'Riordan W, Pullman J, Tambyah PA, Miró JM, Fowler VG, Barriere SL, Kitt MM, Corey GR. A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study. BMC Infect Dis. 2014; 14:289. PMID: 24884578; PMCID: PMC4048626.
      9. Rubinstein E, Stryjewski ME, Barriere SL. Clinical utility of telavancin for treatment of hospital-acquired pneumonia: focus on non-ventilator-associated pneumonia. Infect Drug Resist. 2014; 7:129-35. PMID: 24876786; PMCID: PMC4035308.
      10. Barriere SL, Stryjewski ME, Corey GR, Genter FC, Rubinstein E. Effect of vancomycin serum trough levels on outcomes in patients with nosocomial pneumonia due to Staphylococcus aureus: a retrospective, post hoc, subgroup analysis of the Phase 3 ATTAIN studies. BMC Infect Dis. 2014; 14:183. PMID: 24708675; PMCID: PMC4101862.
      11. Barriere SL. The ATTAIN trials: efficacy and safety of telavancin compared with vancomycin for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia. Future Microbiol. 2014; 9(3):281-9. PMID: 24450506.
        View in: PubMed
      12. Corey GR, Kollef MH, Shorr AF, Rubinstein E, Stryjewski ME, Hopkins A, Barriere SL. Telavancin for hospital-acquired pneumonia: clinical response and 28-day survival. Antimicrob Agents Chemother. 2014; 58(4):2030-7. PMID: 24419353; PMCID: PMC4023742.
      13. Torres A, Rubinstein E, Corey GR, Stryjewski ME, Barriere SL. Analysis of Phase 3 telavancin nosocomial pneumonia data excluding patients with severe renal impairment and acute renal failure. J Antimicrob Chemother. 2014 Apr; 69(4):1119-26. PMID: 24398339; PMCID: PMC4023300.
      14. Ero MP, Harvey NR, Harbert JL, Janc JW, Chin KH, Barriere SL. Impact of telavancin on prothrombin time and activated partial thromboplastin time as determined using point-of-care coagulometers. J Thromb Thrombolysis. 2014; 38(2):235-40. PMID: 24132401.
        View in: PubMed
      15. Stryjewski ME, Barriere SL, Rubinstein E, Genter FC, Lentnek AL, Magana-Aquino M, Luna CM, Niederman MS, Torres A, Corey GR. Telavancin versus vancomycin for bacteraemic hospital-acquired pneumonia. Int J Antimicrob Agents. 2013 Oct; 42(4):367-9. PMID: 23891527.
        View in: PubMed
      16. Krause KM, Blais J, Lewis SR, Lunde CS, Barriere SL, Friedland HD, Kitt MM, Benton BM. In vitro activity of telavancin and occurrence of vancomycin heteroresistance in isolates from patients enrolled in phase 3 clinical trials of hospital-acquired pneumonia. Diagn Microbiol Infect Dis. 2012 Dec; 74(4):429-31. PMID: 23083812.
        View in: PubMed
      17. Stryjewski ME, Potgieter PD, Li YP, Barriere SL, Churukian A, Kingsley J, Corey GR. TD-1792 versus vancomycin for treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother. 2012 Nov; 56(11):5476-83. PMID: 22869571; PMCID: PMC3486540.
      18. Stryjewski ME, Barriere SL, O'Riordan W, Dunbar LM, Hopkins A, Genter FC, Corey GR. Efficacy of telavancin in patients with specific types of complicated skin and skin structure infections. J Antimicrob Chemother. 2012 Jun; 67(6):1496-502. PMID: 22416054.
        View in: PubMed
      19. Samara E, Shaw JP, Barriere SL, Wong SL, Worboys P. Population pharmacokinetics of telavancin in healthy subjects and patients with infections. Antimicrob Agents Chemother. 2012 Apr; 56(4):2067-73. PMID: 22252798; PMCID: PMC3318396.
      20. Lodise TP, Butterfield JM, Hegde SS, Samara E, Barriere SL. Telavancin pharmacokinetics and pharmacodynamics in patients with complicated skin and skin structure infections and various degrees of renal function. Antimicrob Agents Chemother. 2012 Apr; 56(4):2062-6. PMID: 22252799; PMCID: PMC3318336.
      21. Sharma-Kuinkel BK, Ahn SH, Rude TH, Zhang Y, Tong SY, Ruffin F, Genter FC, Braughton KR, Deleo FR, Barriere SL, Fowler VG. Presence of genes encoding panton-valentine leukocidin is not the primary determinant of outcome in patients with hospital-acquired pneumonia due to Staphylococcus aureus. J Clin Microbiol. 2012 Mar; 50(3):848-56. PMID: 22205797; PMCID: PMC3295120.
      22. Nienaber JJ, Sharma Kuinkel BK, Clarke-Pearson M, Lamlertthon S, Park L, Rude TH, Barriere S, Woods CW, Chu VH, Marín M, Bukovski S, Garcia P, Corey GR, Korman T, Doco-Lecompte T, Murdoch DR, Reller LB, Fowler VG. Methicillin-susceptible Staphylococcus aureus endocarditis isolates are associated with clonal complex 30 genotype and a distinct repertoire of enterotoxins and adhesins. J Infect Dis. 2011 Sep 1; 204(5):704-13. PMID: 21844296; PMCID: PMC3156104.
      23. Barriere SL, Goldberg MR, Janc JW, Higgins DL, Macy PA, Adcock DM. Effects of telavancin on coagulation test results. Int J Clin Pract. 2011 Jul; 65(7):784-9. PMID: 21564449.
        View in: PubMed
      24. Rubinstein E, Lalani T, Corey GR, Kanafani ZA, Nannini EC, Rocha MG, Rahav G, Niederman MS, Kollef MH, Shorr AF, Lee PC, Lentnek AL, Luna CM, Fagon JY, Torres A, Kitt MM, Genter FC, Barriere SL, Friedland HD, Stryjewski ME. Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens. Clin Infect Dis. 2011 Jan 1; 52(1):31-40. PMID: 21148517; PMCID: PMC3060890.
      25. Barriere SL. ATLAS trials: efficacy and safety of telavancin compared with vancomycin for the treatment of skin infections. Future Microbiol. 2010 Dec; 5(12):1765-73. PMID: 21080861.
        View in: PubMed
      26. Krause KM, Barriere SL, Kitt MM, Benton BM. In vitro activity of telavancin against Gram-positive isolates from complicated skin and skin structure infections: results from 2 phase 3 (ATLAS) clinical studies. Diagn Microbiol Infect Dis. 2010 Oct; 68(2):181-5. PMID: 20846593.
        View in: PubMed
      27. Barriere SL. Challenges in the design and conduct of clinical trials for hospital-acquired pneumonia and ventilator-associated pneumonia: an industry perspective. Clin Infect Dis. 2010 Aug 1; 51 Suppl 1:S4-9. PMID: 20597670.
        View in: PubMed
      28. Goldberg MR, Wong SL, Shaw JP, Kitt MM, Barriere SL. Single-dose pharmacokinetics and tolerability of telavancin in elderly men and women. Pharmacotherapy. 2010 Aug; 30(8):806-11. PMID: 20653356.
        View in: PubMed
      29. Wong SL, Goldberg MR, Ballow CH, Kitt MM, Barriere SL. Effect of Telavancin on the pharmacokinetics of the cytochrome P450 3A probe substrate midazolam: a randomized, double-blind, crossover study in healthy subjects. Pharmacotherapy. 2010 Feb; 30(2):136-43. PMID: 20099988.
        View in: PubMed
      30. Goldberg MR, Wong SL, Shaw JP, Kitt MM, Barriere SL. Lack of effect of moderate hepatic impairment on the pharmacokinetics of telavancin. Pharmacotherapy. 2010 Jan; 30(1):35-42. PMID: 20030471.
        View in: PubMed
      31. Bae IG, Tonthat GT, Stryjewski ME, Rude TH, Reilly LF, Barriere SL, Genter FC, Corey GR, Fowler VG. Presence of genes encoding the panton-valentine leukocidin exotoxin is not the primary determinant of outcome in patients with complicated skin and skin structure infections due to methicillin-resistant Staphylococcus aureus: results of a multinational trial. J Clin Microbiol. 2009 Dec; 47(12):3952-7. PMID: 19846653; PMCID: PMC2786648.
      32. Patel JH, Churchwell MD, Seroogy JD, Barriere SL, Grio M, Mueller B. Telavancin and hydroxy propyl-beta-cyclodextrin clearance during continuous renal replacement therapy: an in vitro study. Int J Artif Organs. 2009 Oct; 32(10):745-51. PMID: 19943236.
        View in: PubMed
      33. Wong SL, Sörgel F, Kinzig M, Goldberg MR, Kitt MM, Barriere SL. Lack of pharmacokinetic drug interactions following concomitant administration of telavancin with aztreonam or piperacillin/tazobactam in healthy participants. J Clin Pharmacol. 2009 Jul; 49(7):816-23. PMID: 19443680.
        View in: PubMed
      34. Wilson SE, O'Riordan W, Hopkins A, Friedland HD, Barriere SL, Kitt MM. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections associated with surgical procedures. Am J Surg. 2009 Jun; 197(6):791-6. PMID: 19095213.
        View in: PubMed
      35. Laohavaleeson S, Barriere SL, Nicolau DP, Kuti JL. Cost-effectiveness of telavancin versus vancomycin for treatment of complicated skin and skin structure infections. Pharmacotherapy. 2008 Dec; 28(12):1471-82. PMID: 19025428.
        View in: PubMed
      36. Wong SL, Barriere SL, Kitt MM, Goldberg MR. Multiple-dose pharmacokinetics of intravenous telavancin in healthy male and female subjects. J Antimicrob Chemother. 2008 Oct; 62(4):780-3. PMID: 18586659.
        View in: PubMed
      37. Stryjewski ME, Graham DR, Wilson SE, O'Riordan W, Young D, Lentnek A, Ross DP, Fowler VG, Hopkins A, Friedland HD, Barriere SL, Kitt MM, Corey GR. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin Infect Dis. 2008 Jun 1; 46(11):1683-93. PMID: 18444791.
        View in: PubMed
      38. Lodise TP, Gotfried M, Barriere S, Drusano GL. Telavancin penetration into human epithelial lining fluid determined by population pharmacokinetic modeling and Monte Carlo simulation. Antimicrob Agents Chemother. 2008 Jul; 52(7):2300-4. PMID: 18426898; PMCID: PMC2443895.
      39. Campbell SJ, Deshmukh HS, Nelson CL, Bae IG, Stryjewski ME, Federspiel JJ, Tonthat GT, Rude TH, Barriere SL, Corey R, Fowler VG. Genotypic characteristics of Staphylococcus aureus isolates from a multinational trial of complicated skin and skin structure infections. J Clin Microbiol. 2008 Feb; 46(2):678-84. PMID: 18077636; PMCID: PMC2238106.
      40. Gotfried MH, Shaw JP, Benton BM, Krause KM, Goldberg MR, Kitt MM, Barriere SL. Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics. Antimicrob Agents Chemother. 2008 Jan; 52(1):92-7. PMID: 17923490; PMCID: PMC2223919.
      41. Stryjewski ME, Chu VH, O'Riordan WD, Warren BL, Dunbar LM, Young DM, Vallée M, Fowler VG, Morganroth J, Barriere SL, Kitt MM, Corey GR. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study. Antimicrob Agents Chemother. 2006 Mar; 50(3):862-7. PMID: 16495243; PMCID: PMC1426424.
      42. Stryjewski ME, O'Riordan WD, Lau WK, Pien FD, Dunbar LM, Vallee M, Fowler VG, Chu VH, Spencer E, Barriere SL, Kitt MM, Cabell CH, Corey GR. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria. Clin Infect Dis. 2005 Jun 1; 40(11):1601-7. PMID: 15889357.
        View in: PubMed
      43. Shaw JP, Seroogy J, Kaniga K, Higgins DL, Kitt M, Barriere S. Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects. Antimicrob Agents Chemother. 2005 Jan; 49(1):195-201. PMID: 15616296; PMCID: PMC538848.
      44. Barriere S, Genter F, Spencer E, Kitt M, Hoelscher D, Morganroth J. Effects of a new antibacterial, telavancin, on cardiac repolarization (QTc interval duration) in healthy subjects. J Clin Pharmacol. 2004 Jul; 44(7):689-95. PMID: 15199073.
        View in: PubMed
      45. Nichols RL, Graham DR, Barriere SL, Rodgers A, Wilson SE, Zervos M, Dunn DL, Kreter B. Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. Synercid Skin and Skin Structure Infection Group. J Antimicrob Chemother. 1999 Aug; 44(2):263-73. PMID: 10473234.
        View in: PubMed
      46. Jaresko GS, Barriere SL, Johnson BL. Serum and blister fluid pharmacokinetics and bactericidal activities of ampicillin-sulbactam, cefotetan, cefoxitin, ceftizoxime, and ticarcillin-clavulanate. Antimicrob Agents Chemother. 1992 Oct; 36(10):2233-8. PMID: 1444304; PMCID: PMC245482.
      47. Barriere SL. Pharmacology and pharmacokinetics of cefprozil. Clin Infect Dis. 1992 Jun; 14 Suppl 2:S184-8; discussion S195-6. PMID: 1617036.
        View in: PubMed
      48. Barriere SL, Guglielmo BJ. Gram-negative sepsis, the sepsis syndrome, and the role of antiendotoxin monoclonal antibodies. Clin Pharm. 1992 Mar; 11(3):223-35. PMID: 1611812.
        View in: PubMed
      49. Kalman D, Barriere SL, Johnson BL. Pharmacokinetic disposition and bactericidal activities of cefepime, ceftazidime, and cefoperazone in serum and blister fluid. Antimicrob Agents Chemother. 1992 Feb; 36(2):453-7. PMID: 1605609; PMCID: PMC188456.
      50. Kaatz GW, Seo SM, Barriere SL, Albrecht LM, Rybak MJ. Development of resistance to fleroxacin during therapy of experimental methicillin-susceptible Staphylococcus aureus endocarditis. Antimicrob Agents Chemother. 1991 Aug; 35(8):1547-50. PMID: 1929325; PMCID: PMC245216.
      51. Kalman D, Barriere SL. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis. 1991 Jan; 163(1):201-3. PMID: 1984470.
        View in: PubMed
      52. Barriere SL. Monotherapy versus combination antimicrobial therapy: a review. Pharmacotherapy. 1991; 11(2 ( Pt 2)):64S-71S. PMID: 2041834.
        View in: PubMed
      53. Barriere SL, Catlin DH, Orlando PL, Noe A, Frost RW. Alteration in the pharmacokinetic disposition of ciprofloxacin by simultaneous administration of azlocillin. Antimicrob Agents Chemother. 1990 May; 34(5):823-6. PMID: 2360821; PMCID: PMC171699.
      54. Orlando PL, Barriere SL, Hindler JA, Frost RW. Serum bactericidal activity from intravenous ciprofloxacin and azlocillin given alone and in combination to healthy subjects. Diagn Microbiol Infect Dis. 1990 Mar-Apr; 13(2):93-7. PMID: 2114954.
        View in: PubMed
      55. Kaatz GW, Seo SM, Barriere SL, Albrecht LM, Rybak MJ. Efficacy of ofloxacin in experimental Staphylococcus aureus endocarditis. Antimicrob Agents Chemother. 1990 Feb; 34(2):257-60. PMID: 2327773; PMCID: PMC171568.
      56. Kaatz GW, Seo SM, Barriere SL, Albrecht LM, Rybak MJ. Ciprofloxacin and rifampin, alone and in combination, for therapy of experimental Staphylococcus aureus endocarditis. Antimicrob Agents Chemother. 1989 Aug; 33(8):1184-7. PMID: 2802547; PMCID: PMC172621.
      57. Rodondi LC, Flaherty JF, Schoenfeld P, Barriere SL, Gambertoglio JG. Influence of coadministration on the pharmacokinetics of mezlocillin and cefotaxime in healthy volunteers and in patients with renal failure. Clin Pharmacol Ther. 1989 May; 45(5):527-34. PMID: 2721108.
        View in: PubMed
      58. Kaatz GW, Seo SM, Barriere SL, Albrecht LM, Rybak MJ. Efficacy of fleroxacin in experimental methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob Agents Chemother. 1989 Apr; 33(4):519-21. PMID: 2499251; PMCID: PMC172471.
      59. Barriere SL, Kaatz GW, Seo SM. Enhanced elimination of ciprofloxacin after multiple-dose administration of rifampin to rabbits. Antimicrob Agents Chemother. 1989 Apr; 33(4):589-90. PMID: 2729952; PMCID: PMC172487.
      60. Moore ES, Jimenez M, Barriere SL, Cimino ML, Fekety FR. Additive and synergistic bactericidal activity contributed by desacetylcefotaxime during cefotaxime therapy. Clin Pharm. 1988 Dec; 7(12):901-5. PMID: 3208502.
        View in: PubMed
      61. Lam YW, Duroux MH, Gambertoglio JG, Barriere SL, Guglielmo BJ. Effect of protein binding on serum bactericidal activities of ceftazidime and cefoperazone in healthy volunteers. Antimicrob Agents Chemother. 1988 Mar; 32(3):298-302. PMID: 3284457; PMCID: PMC172163.
      62. Kaatz GW, Barriere SL, Schaberg DR, Fekety R. The emergence of resistance to ciprofloxacin during treatment of experimental Staphylococcus aureus endocarditis. J Antimicrob Chemother. 1987 Nov; 20(5):753-8. PMID: 3429376.
        View in: PubMed
      63. Barriere SL, Kaatz GW, Schaberg DR, Fekety R. Altered pharmacokinetic disposition of ciprofloxacin and vancomycin after single and multiple doses in rabbits. Antimicrob Agents Chemother. 1987 Jul; 31(7):1075-8. PMID: 3662471; PMCID: PMC174874.
      64. Flaherty JF, Barriere SL, Mordenti J, Gambertoglio JG. Effect of dose on pharmacokinetics and serum bactericidal activity of mezlocillin. Antimicrob Agents Chemother. 1987 Jun; 31(6):895-8. PMID: 3619421; PMCID: PMC284206.
      65. Kaatz GW, Barriere SL, Schaberg DR, Fekety R. Ciprofloxacin versus vancomycin in the therapy of experimental methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob Agents Chemother. 1987 Apr; 31(4):527-30. PMID: 3649202; PMCID: PMC174771.
      66. Guglielmo BJ, Flaherty JF, Batman R, Barriere SL, Gambertoglio JG. Comparative pharmacokinetics of low- and high-dose ticarcillin. Antimicrob Agents Chemother. 1986 Sep; 30(3):359-60. PMID: 3777901; PMCID: PMC180559.
      67. Barriere SL, Ozasa DC, Mordenti J. Assessment of serum bactericidal activity after administration of cefoperazone, cefotaxime, ceftizoxime, and moxalactam to healthy subjects. Antimicrob Agents Chemother. 1985 Jul; 28(1):55-7. PMID: 3929680; PMCID: PMC176309.
      68. Barriere SL, Ely E, Kapusnik JE, Gambertoglio JG. Analysis of a new method for assessing activity of combinations of antimicrobials: area under the bactericidal activity curve. J Antimicrob Chemother. 1985 Jul; 16(1):49-59. PMID: 3930461.
        View in: PubMed
      69. Gambertoglio JG, Alexander DP, Barriere SL. Cefmenoxime pharmacokinetics in healthy volunteers and subjects with renal insufficiency and on hemodialysis. Antimicrob Agents Chemother. 1984 Dec; 26(6):845-9. PMID: 6098220; PMCID: PMC180037.
      70. Barriere SL, Gambertoglio JG, Alexander DP, Stagg RJ, Conte JE. Pharmacokinetic disposition of cefonicid in patients with renal failure and receiving hemodialysis. Rev Infect Dis. 1984 Nov-Dec; 6 Suppl 4:S809-15. PMID: 6522922.
        View in: PubMed
      71. Barriere SL, Flaherty JF. Third-generation cephalosporins: a critical evaluation. Clin Pharm. 1984 Jul-Aug; 3(4):351-73. PMID: 6432420.
        View in: PubMed
      72. Gambertoglio JG, Barriere SL, Lin ET, Conte JE. Amdinocillin pharmacokinetics. Simultaneous administration with cephalothin and cerebrospinal fluid penetration. Am J Med. 1983 Aug 29; 75(2A):54-9. PMID: 6311006.
        View in: PubMed
      73. Noonan IA, Gambertoglio JG, Barriere SL, Conte JE, Lin ET. High-performance liquid chromatographic determination of cefmenoxime (AB-50912) in human plasma and urine. J Chromatogr. 1983 Apr 8; 273(2):458-63. PMID: 6306028.
        View in: PubMed
      74. Barriere SL, Hatheway GJ, Gambertoglio JG, Lin ET, Conte JE. Pharmacokinetics of cefonicid, a new broad-spectrum cephalosporin. Antimicrob Agents Chemother. 1982 Jun; 21(6):935-8. PMID: 7114840; PMCID: PMC182048.
      75. Barriere SL, Gambertoglio JG, Lin ET, Conte JE. Multiple-dose pharmacokinetics of amdinocillin in healthy volunteers. Antimicrob Agents Chemother. 1982 Jan; 21(1):54-7. PMID: 6282208; PMCID: PMC181828.
      76. King CY, Barriere SL. Analysis of the in vitro interaction between vancomycin and cholestyramine. Antimicrob Agents Chemother. 1981 Feb; 19(2):326-7. PMID: 6812491; PMCID: PMC181420.
      77. Gambertoglio JG, Barriere SL, Lin ET, Conte JE. Pharmacokinetics of mecillinam in health subjects. Antimicrob Agents Chemother. 1980 Dec; 18(6):952-6. PMID: 6263180; PMCID: PMC352996.
      Steven's Networks
      Related Concepts
      Derived automatically from this person's publications.
      _
      Co-Authors
      People in Profiles who have published with this person.
      _
      Related Authors
      People who share related concepts with this person.
      _
      Back to TOP